Desjardins Global Asset Management Inc. Takes Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Desjardins Global Asset Management Inc. purchased a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 15,793 shares of the specialty pharmaceutical company's stock, valued at approximately $1,943,000.

Several other hedge funds have also recently added to or reduced their stakes in JAZZ. Vanguard Group Inc. lifted its position in shares of Jazz Pharmaceuticals by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company's stock worth $825,705,000 after purchasing an additional 29,960 shares during the period. Wellington Management Group LLP lifted its stake in shares of Jazz Pharmaceuticals by 7.5% in the first quarter. Wellington Management Group LLP now owns 2,625,134 shares of the specialty pharmaceutical company's stock worth $408,654,000 after buying an additional 184,124 shares in the last quarter. State Street Corp grew its holdings in shares of Jazz Pharmaceuticals by 1.8% during the second quarter. State Street Corp now owns 2,372,395 shares of the specialty pharmaceutical company's stock valued at $294,106,000 after buying an additional 42,703 shares during the last quarter. LSV Asset Management boosted its stake in Jazz Pharmaceuticals by 2.4% during the 3rd quarter. LSV Asset Management now owns 2,372,177 shares of the specialty pharmaceutical company's stock valued at $307,055,000 after purchasing an additional 55,630 shares during the last quarter. Finally, FMR LLC boosted its position in shares of Jazz Pharmaceuticals by 8.1% during the third quarter. FMR LLC now owns 1,333,129 shares of the specialty pharmaceutical company's stock valued at $172,560,000 after buying an additional 100,349 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Trading Down 1.7 %

JAZZ stock traded down $1.80 during trading on Wednesday, hitting $107.10. The company had a trading volume of 592,713 shares, compared to its average volume of 614,110. The firm has a market capitalization of $6.75 billion, a P/E ratio of 17.55, a PEG ratio of 1.53 and a beta of 0.59. The company has a quick ratio of 1.85, a current ratio of 2.24 and a debt-to-equity ratio of 1.37. Jazz Pharmaceuticals plc has a 52-week low of $106.61 and a 52-week high of $146.70. The company has a 50 day simple moving average of $120.99 and a 200-day simple moving average of $122.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing the consensus estimate of $4.44 by ($0.04). The firm had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. As a group, research analysts forecast that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,936 shares of the stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the sale, the chief accounting officer now directly owns 8,364 shares of the company's stock, valued at $1,000,668.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CAO Patricia Carr sold 1,936 shares of the company's stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the transaction, the chief accounting officer now directly owns 8,364 shares of the company's stock, valued at $1,000,668.96. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Philip L. Johnson acquired 12,000 shares of the firm's stock in a transaction dated Friday, March 1st. The shares were acquired at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the acquisition, the chief financial officer now owns 27,932 shares in the company, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. 4.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have weighed in on JAZZ shares. HC Wainwright lowered their target price on Jazz Pharmaceuticals from $204.00 to $200.00 and set a "buy" rating on the stock in a report on Thursday, March 14th. Stifel Nicolaus upped their price objective on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a "buy" rating in a research note on Friday, March 15th. StockNews.com raised Jazz Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Tuesday, January 30th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $180.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. Finally, Piper Sandler boosted their target price on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an "overweight" rating in a report on Wednesday, March 20th. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $195.08.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.